Warrior Met Coal, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Walter J. Scheller
- Full Time Employees
- 1,485
- Sector
- Energy minerals
- Industry
- Coal
- Address
- 16243 Highway 216 Brookwood AL United States 35444
- IPO Date
- Apr 13, 2017
- CIK
- 0001691303
- Website
- warriormetcoal.com
- Similar Companies
- Business
- Warrior Met Coal, Inc. Warrior Met Coal, Inc. (NYSE: HCC) is a U.S.-based producer and exporter of premium quality metallurgical coal, also known as hard coking coal (HCC) or steel-making coal, primarily sourced from the Blue Creek coal seam in Alabama. The company operates highly efficient longwall underground mines, including Mine No. 4 and Mine No. 7, with a third mine at Blue Creek under development; it produces coal characterized by low sulfur, high coke strength after reaction (CSR), high fluidity, high drum index, and low-to-medium volatility, making it ideal as a base feed for blast furnace steel producers. Warrior also generates ancillary revenues from natural gas extracted as a byproduct from its underground mining operations and from royalties on leased properties. The company exports its metallurgical coal to a diversified customer base of steel manufacturers primarily in Europe, South America, and Asia, leveraging its strategic location approximately 300 miles from the McDuffie Terminal at the Port of Mobile, Alabama, which provides the shortest mine-to-port distance among U.S. met coal producers and enables competitive transit times. Warrior emphasizes operational efficiency, safety—with an incidence rate 65% lower than the U.S. national rate for underground mining in 2024—and environmental stewardship, including responsible water management and investments in mine infrastructure above normal sustaining capital levels. Founded in 2015 and headquartered in Brookwood, Alabama, Warrior Met Coal operates exclusively in the metallurgical coal segment of the materials sector, with approximately 1,300 employees and a focus on the global steel industry supply chain. In recent developments, the company executed an early startup of longwall operations at its Blue Creek mine, raised its 2025 production guidance by 10%, and expanded its reserve base through the acquisition of a federal coal lease adding 58 million short tons of high-quality steelmaking coal reserves.
Company News
Warrior Met Coal Q3 Earnings Call Highlights
Warrior Met Coal, Inc. (HCC) Q3 2026 Earnings Call Transcript
Warrior Met Coal (HCC) Lags Q3 Earnings Estimates
Warrior Reports Third Quarter 2026 Results
Dividend Announcements: October 24-30, 2026 (Part 2 Of 2)
Warrior Met Coal Declares Special Cash Dividend
Warrior Met Coal (HCC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Warrior Announces Regular Quarterly Cash Dividend
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Warrior Sets Date for Third Quarter 2026 Earnings Announcement and Investor Conference Call
Black Bear Value Partners Q3 2026 - Top 5 Businesses We Own
Warrior Met Coal: A Volume Story Still Priced Like A Coal Price Bet
Warren Buffett's Succession Triggers Search for His Spiritual Successors
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Jupiter Topco LLC Takes $1.83 Million Position in Warrior Met Coal $HCC
Top 3 Materials Stocks That Could Sink Your Portfolio This Month